Drugs / Cannabis oil
Cannabis oil
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06807762 | Mar → Jun 2025 overdue | — | GreenCare Pharma | Recruiting | No outcome recorded |
| Phase 1 | NCT04841993 | Dec 2018 → Dec 2019 | cannabis dependence | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06435299 | Jan 2027 → Mar 2029 expected | — | University Hospital, Brest | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05219370 | Jul → Dec 2022 | attention deficit-hyperactivity disorder | Brlev Agricultural Crops Ltd | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03639064 | Dec 2020 → Dec 2022 | Parkinson disease | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT03929835 | Sep 2020 → Sep 2022 | hidradenitis suppurativa | TO Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03664141 | Sep 2018 → Aug 2019 | eating disorder, protein-energy malnutrition | Assaf-Harofeh Medical Center | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06863740 | Jul 2025 → Dec 2026 expected | restless legs syndrome | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06946940 Comparator | May 2024 → May 2026 overdue | fibromyalgia | Rambam Health Care Campus | Recruiting | No outcome recorded |
| Phase 3 | NCT05212493 Comparator | Nov 2019 → Dec 2021 | autism spectrum disorder | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cannabis oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05212493 ↗ |
| Known as | CanniMed | “Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®.” NCT03639064 ↗ |
| Known as | LGP THC25:CBD25 | “Therefore, sublingual LGP THC25:CBD25 oil has been selected for its balanced ratio, simple administration route, and expected tolerability, to evaluate its efficacy and safety...” NCT06435299 ↗ |
| Route | Oral | “Cannabis oil will be administered orally once per day” NCT03639064 ↗ |